Outlook Refiles Ophthalmic Bevacizumab In US
Follows Withdrawal Of Earlier BLA After FDA Asked For Additional Information
Outlook Therapeutics has confirmed the re-submission of its proposed ophthalmic bevacizumab with the US Food and Drug Administration, after the agency requested further information.
